Trimethylamine N-Oxide, a Gut Microbiota-Derived Metabolite, Is Associated with Cardiovascular Risk in Psoriasis: A

Mariusz Sikora1, Norbert Kiss2, Albert Stec3

  • 1Department of Dermatology, Medical University of Warsaw, Koszykowa 82a, 02-008, Warsaw, Poland. msikora@wum.edu.pl.

Abstract

Insights

Trimethylamine N-oxide (TMAO) levels are higher in psoriasis patients and independently predict cardiovascular risk, suggesting TMAO as a potential biomarker for atherosclerosis in this population.

Area of Science:

  • Metabolomics
  • Cardiovascular Research
  • Dermatology

Background:

  • Trimethylamine N-oxide (TMAO), a gut microbiota metabolite, is implicated in atherosclerosis and cardiovascular diseases.
  • Psoriasis patients face elevated cardiovascular risk not fully explained by traditional biomarkers.

Purpose of the Study:

  • To measure TMAO concentration in psoriasis patients.
  • To investigate the association between TMAO and cardiovascular risk in psoriasis.

Main Methods:

  • Evaluated plasma TMAO in 72 psoriasis patients and 40 controls using high-performance liquid chromatography.
  • Assessed cardiovascular risk using Framingham, QRISK2, AHA/ACC, and Reynolds risk scores.

Main Results:

  • Psoriasis patients exhibited significantly higher TMAO levels compared to controls (195.68 ng/ml vs 126.06 ng/ml).
  • TMAO correlated with age, cholesterol, triglycerides, and blood pressure.
  • TMAO was identified as an independent predictor of cardiovascular risk.

Conclusions:

  • TMAO shows promise as a biomarker for atherosclerosis in psoriasis.
  • TMAO may serve as a link between gut dysbiosis and cardiovascular complications in psoriasis.